Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study
PHASE4CompletedINTERVENTIONAL
Enrollment
24
Participants
Timeline
Start Date
Not specified
Study Completion Date
October 31, 2003
Conditions
Inflammation
Interventions
DRUG
Pioglitazone 15mg
DRUG
pioglitazone 30mg
DRUG
placebo
Trial Locations (1)
14226
Millard Fillmore gates Hospital, Buffalo
All Listed Sponsors
collaborator
Takeda Pharmaceuticals North America, Inc.
INDUSTRY
lead
University at Buffalo
OTHER
NCT01161394 - Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study | Biotech Hunter | Biotech Hunter